Lunai Bioworks Statistics
Total Valuation
Lunai Bioworks has a market cap or net worth of 829,678. The enterprise value is 606,417.
| Market Cap | 829,678 |
| Enterprise Value | 606,417 |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lunai Bioworks has 5.03 million shares outstanding. The number of shares has increased by 62.89% in one year.
| Current Share Class | 5.03M |
| Shares Outstanding | 5.03M |
| Shares Change (YoY) | +62.89% |
| Shares Change (QoQ) | +45.32% |
| Owned by Insiders (%) | 15.81% |
| Owned by Institutions (%) | 3.90% |
| Float | 4.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.96 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.46 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -54.11% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 87.71% |
| Weighted Average Cost of Capital (WACC) | 10.22% |
| Revenue Per Employee | 4,333 |
| Profits Per Employee | -296,873 |
| Employee Count | 12 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.02% in the last 52 weeks. The beta is 0.35, so Lunai Bioworks's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -98.02% |
| 50-Day Moving Average | 1.61 |
| 200-Day Moving Average | 2.91 |
| Relative Strength Index (RSI) | 13.40 |
| Average Volume (20 Days) | 737,974 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.29 |
Income Statement
In the last 12 months, Lunai Bioworks had revenue of 51,992 and -3.56 million in losses. Loss per share was -1.06.
| Revenue | 51,992 |
| Gross Profit | 51,992 |
| Operating Income | -7.87M |
| Pretax Income | -3.56M |
| Net Income | -3.56M |
| EBITDA | -7.81M |
| EBIT | -7.87M |
| Loss Per Share | -1.06 |
Balance Sheet
The company has 1.71 million in cash and 1.49 million in debt, with a net cash position of 223,264 or 0.04 per share.
| Cash & Cash Equivalents | 1.71M |
| Total Debt | 1.49M |
| Net Cash | 223,264 |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | -9.02M |
| Book Value Per Share | -1.96 |
| Working Capital | -16.87M |
Cash Flow
In the last 12 months, operating cash flow was -5.29 million and capital expenditures -1,238, giving a free cash flow of -5.29 million.
| Operating Cash Flow | -5.29M |
| Capital Expenditures | -1,238 |
| Depreciation & Amortization | 58,418 |
| Net Borrowing | 593,629 |
| Free Cash Flow | -5.29M |
| FCF Per Share | -1.05 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -15,129.29% |
| Pretax Margin | -6,851.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lunai Bioworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -62.89% |
| Shareholder Yield | -62.89% |
| Earnings Yield | -643.19% |
| FCF Yield | -637.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 22, 2026. It was a reverse split with a ratio of 0.125.
| Last Split Date | May 22, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
Lunai Bioworks has an Altman Z-Score of -76.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -76.19 |
| Piotroski F-Score | 1 |